December 6, 2017

Posting a $51.8 million third-quarter loss, Fred’s said that it is exploring strategic alternatives for non-core businesses, including its specialty pharmacy business and real estate. 

December 6, 2017

Shingrix is now approved in Canada and U.S. for the prevention of herpes zoster in adults aged 50 years and above.

December 5, 2017

In 2016, an estimated 37 million people were living with HIV-1 globally, and 1.8 million people became newly infected with the virus.

December 1, 2017

The companies said Mylan expects to potentially be the first company to offer a Herceptin biosimilar, and that the approval clears a path for the company to commercialize the biosimilar in various global markets.

November 30, 2017

Initially, Walgreens and OraSure will provide the OraQuick In-Home HIV Test Retail Access Cards to Housing Works, a New-York City-based public health organization.

November 27, 2017

Hepatitis C patients managed jointly by this clinic-pharmacy collaboration had a shorter average prescribed time-to-therapy and lower copays.

November 16, 2017

The acquisition of LDI Integrated Pharmacy Services marks Diplomat’s second PBM acquisition this month, having acquired National Pharmaceutical Services on Nov. 6. 

November 14, 2017

The Marine Stewardship Council is looking to inform customers where their supplements originated from. 

November 9, 2017

The launch adds to Mylan’s oncology portfolio, which it said contains more than 40 products. 

November 7, 2017
Diplomat’s CEO and chairman, Phil Hagerman, said the acquisition of National Pharmaceutical Services is a way of responding to patient and employer demands for flexible methods aimed at improving outcomes and reduced costs.
November 7, 2017

This acquisition will enhance McKesson’s commercialization solutions for manufacturers of branded, specialty, generic and biosimilar drugs, including comprehensive patient support, or “hub,” services.

November 2, 2017
The mantle cell lymphoma treatment is set to be dispensed by a limited group of specialty pharmacies, which include Diplomat Pharmacy and Avella Specialty Pharmacy.
October 31, 2017

Diplomat Pharmacy has a new member of its executive leadership team who brings with her more than a quarter-century of industry experience.

October 19, 2017

Yescarta, from Gilead’s recently acquired company Kite, was approved to treat relapsed or refractory large B-cell lymphoma following two or more lines of systemic therapy.

October 18, 2017

As specialty growth looks set to plateau, the drug class continues to see its share of per-capita spending increase, with a decline in spending on traditional medicines creating space for more specialty share.

October 16, 2017

According to the World Health Organization, roughly one-third of patients diagnosed with plaque psoriasis is younger than 20 years of age, and adolescents in particular have limited treatment options.

October 10, 2017

The drug was approved to treat certain cases of advanced or metastatic breast cancer, either alone or in combination with Faslodex.

October 6, 2017

The newly re-launched product is Health Canada compliant and has been available for purchase online since Sept.  29.

October 3, 2017
With the acquisition, EnvoyHealth can now offer its healthcare partners such services as IT outsourcing, consulting and product development.
September 28, 2017

Verzenio works by blocking certain molecules that are involved in cancer cell growth, and it joins two previously approved drugs in this class — palbociclib (Pfizer’s Ibrance) and ribociclib (Novartis’ Kisqali). 

September 25, 2017

The new indication’s approval marks the 10th new indication for Keytruda in three years, Merck said. 

September 22, 2017

The Distinguished Service Award is given annually to an individual who has made a sustained contribution to leadership within NASP and the specialty pharmacy industry.

September 22, 2017

Temptime VP global customer development Christopher Caulfield spoke with Drug Store News about how the company’s tools helps pharmacies deliver value to patients and the healthcare system. 

September 20, 2017
In order to realize the estimated $11.4 billion in savings, the Centers for Medicare and Medicaid Services would need to revise the way it currently reimburses for biosimilar drugs.